A core facility for analyzing cancer drug effectiveness and safety
The Chesapeake-Ohio Pharmacokinetics Core for The ETCTN
['FUNDING_OTHER'] · JOHNS HOPKINS UNIVERSITY · NIH-11053627
This study is all about helping improve cancer treatments by looking closely at how drugs work in the body, so patients can get the best possible care and the right dose for their needs.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | JOHNS HOPKINS UNIVERSITY (nih funded) |
| Locations | 1 site (BALTIMORE, UNITED STATES) |
| Trial ID | NIH-11053627 on ClinicalTrials.gov |
What this research studies
The Chesapeake-Ohio Pharmacokinetics Core (ChOP-KC) focuses on providing advanced bioanalytical services to support the development of cancer therapies. This facility collaborates with major institutions to design and integrate clinical pharmacology studies, analyze samples, and interpret data for clinical trials. By analyzing a large number of pharmacokinetic specimens each year, the ChOP-KC aims to enhance the evaluation of new cancer treatments and improve patient care. Patients may benefit from the insights gained through these studies, which aim to optimize drug dosing and effectiveness.
Who could benefit from this research
Good fit: Ideal candidates for this research include cancer patients who are participating in clinical trials and require pharmacokinetic analysis of their treatment.
Not a fit: Patients with non-cancerous conditions or those not involved in clinical trials may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer cancer treatments tailored to individual patient needs.
How similar studies have performed: Previous research has shown success in utilizing pharmacokinetic analysis to improve cancer treatment outcomes, indicating that this approach is both tested and promising.
Where this research is happening
BALTIMORE, UNITED STATES
- JOHNS HOPKINS UNIVERSITY — BALTIMORE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BEUMER, JAN HENDRIK — JOHNS HOPKINS UNIVERSITY
- Study coordinator: BEUMER, JAN HENDRIK
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents, anti-cancer drug, anti-cancer therapy